> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# DexCom CEO Still Expects A Medicare Coverage Decision This Year, Backed By Connect Trial
- URL: https://www.bullished.co/dexcom-ceo-still-expects-a-medicare-coverage-decision-this-year-backed-by-connect-trial-35fa42c7/
- Published: 2026-10-29T21:54:27.000Z
- Updated: 2026-10-29T21:54:27.000Z
- Description: Jake Leach says the timing for type 2 non-insulin coverage is unchanged as DexCom reports 14% U.S. revenue growth.
- Author: Matteo Parrino
- Tags: Earnings, DXCM, Industry: Healthcare

[DexCom](https://www.bullished.co/tag/dxcm/), which makes continuous glucose monitors for people with diabetes, still expects Medicare to announce a coverage decision this year for type 2 patients not on insulin, CEO Jake Leach said on the company's third-quarter [earnings call](https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-q3-2026/?ref=bullished.co) Thursday. U.S. revenue grew 14% in the quarter, and the company said it gained share.

## Medicare timing holds

Asked by a Citi analyst whether the timeline had moved, Leach, who is president and CEO, said DexCom has not changed its view on Medicare timing. "Nothing has changed on that front at all," he said.

Leach said the decision-makers "were very aware of the data even before it was published" in the New England Journal of Medicine, though DexCom made sure they had the official notice. The company also sent the publication directly to the medical directors reviewing its Medicare submission.

The Connect trial showed a 1.6% A1c improvement over six months for the DexCom group, a 0.9% difference against the control group. Leach called these the strongest A1c results from the company's randomized trials. He said the journal publication earlier this month is the first in nearly two decades of clinical data on standalone CGM use.

## ADA standards could follow

Answering a William Blair analyst, Leach said Connect is level A evidence, which means a strong recommendation for use in that population. He expects that to shape the ADA Standards of Care, due for an update in the coming weeks, "basically making CGM the standard of care for anybody with diabetes."

Non-insulin users are "not too far behind" insulin users among new patients each quarter, Leach said, though insulin users remain the largest group.

On the next-generation G8 platform, he said the device is built into a 50% smaller volume than G7\. DexCom is still targeting a launch at the end of next year or early 2028, depending on regulatory review.

## The quarter and the outlook

Worldwide revenue was [$1.34 billion](https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-q3-2026/?ref=bullished.co), up 11%, with U.S. revenue of $970 million, up 14%. Leach said the largest share gains came from type 2 customers, including those not on insulin. International revenue rose 5% to $375 million.

Gross margin reached 65.1%, from 61.3% a year earlier. Net income was $275 million, or 73 cents a share. DexCom ended the quarter with about $1.8 billion in cash and announced a new [$1 billion buyback](https://seekingalpha.com/news/4660799-dexcom-announces-1b-share-repurchase-program?ref=bullished.co) after finishing its $1 billion 2026 repurchase goal.

Full-year revenue guidance is now [$5.20 billion to $5.25 billion](https://finance.yahoo.com/healthcare/articles/dexcom-q3-earnings-snapshot-201943390.html?ref=bullished.co), growth of 12% to 13%. The company also said it signed a deal to buy a European distributor business, which will close next year. DexCom's market value was $29.7 billion after Thursday's session.

The ADA update is expected within weeks, and Leach expects the Medicare decision before year-end.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Dexcom Handily Beats Earnings Views, Hikes Sales Guide | Investor's Business Daily](https://www.investors.com/news/technology/dexcom-stock-dexcom-earnings-q3-2026/?ref=bullished.co) — investors.com
- [DexCom: Q3 Earnings Snapshot](https://finance.yahoo.com/healthcare/articles/dexcom-q3-earnings-snapshot-201943390.html?ref=bullished.co) — Associated Press
- [DexCom announces $1B share repurchase program (DXCM:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4660799-dexcom-announces-1b-share-repurchase-program?ref=bullished.co) — seekingalpha.com
- [DexCom: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/dexcom-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [DexCom Non-GAAP EPS of $0.73 beats by $0.06, revenue of $1.34B beats by $10M (NASDAQ:DXCM)](https://seekingalpha.com/news/4660742-dexcom-non-gaap-eps-of-0%5F73-beats-by-0%5F06-revenue-of-1%5F34b-beats-by-10m?ref=bullished.co) — seekingalpha.com

### More on DexCom

- [DexCom Says Lost PBM Coverage Is Under 4% Of U.S. Revenue And Won't Dent 2027 Much](https://www.bullished.co/dexcom-says-lost-pbm-coverage-is-under-4-of-u-s-revenue-and-wont-dent-2027-much-20d90b52/)
- [Dexcom Raises Margin Targets And Plans $1 Billion Buyback After Sales Climb 11%](https://www.bullished.co/dexcom-raises-margin-targets-and-plans-1-billion-buyback-after-sales-climb-11-28dfd644/)

[All DexCom (DXCM) coverage →](https://www.bullished.co/tag/dxcm/)